Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 4/20 | 0.56 |
| ▸ | BRD4 | O60885 | 10/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.45 |
| ▸ | WEE1 | P30291 | 2/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13268240 | 0.93 | CTSC (0.55) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL13268026 | 0.92 | BRD4 (0.61) | CTSCBRD4JAK2JAK3EGFR | |
| SCHEMBL13268024 | 0.89 | CTSC (0.59) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL3108564 | 0.87 | CTSC (0.57) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL12854434 | 0.87 | CTSC (0.57) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL13268225 | 0.85 | JAK1 (0.60) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL13268022 | 0.85 | BRD4 (0.61) | CTSCBRD4JAK2JAK3EGFR | |
| Formic Acid SCHEMBL14482025 | 0.84 | CTSC (0.54) | CTSCBRD4JAK2JAK3CYP3A4 | |
| SCHEMBL13268245 | 0.84 | BRD4 (0.62) | CTSCBRD4JAK2JAK3EGFR | |
| SCHEMBL3117599 | 0.83 | CTSC (0.56) | CTSCBRD4JAK2JAK3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179134-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | CTSC 2069/4885BRD4 789/4885JAK2 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.